Filing Details
- Accession Number:
- 0001056807-13-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-11 17:55:28
- Reporting Period:
- 2013-06-07
- Filing Date:
- 2013-06-11
- Accepted Time:
- 2013-06-11 17:55:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1034842 | Rigel Pharmaceuticals Inc | RIGL | Pharmaceutical Preparations (2834) | 943248524 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
918923 | P L Fund Value Biotechnology | C/O Grosvenor Capital Management Lp 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
1055947 | P/Il L Partners Bvf | C/O Grosvenor Capital Management Lp 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
1056807 | Bvf Inc/Il | C/O Grosvenor Capital Management Lp 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
1102444 | Biotechnology Value Fund Ii Lp | C/O Grosvenor Capital Management Lp 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
1132245 | Bvf Investments Llc | C/O Grosvenor Capital Management Lp 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
1233840 | N Mark Lampert | One Sansome Street, 31St Floor San Francisco CA 94104 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-06-07 | 24,598 | $3.47 | 1,455,414 | No | 4 | P | Indirect | See Explanation of Responses |
Common Stock | Acquisiton | 2013-06-07 | 8,102 | $3.47 | 799,615 | No | 4 | P | Indirect | See Explanation of Responses |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Explanation of Responses |
No | 4 | P | Indirect | See Explanation of Responses |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 6,962,123 | Indirect | See Explanation of Responses |
Footnotes
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVLLC"), BVF Partners L.P. ("Partners"), BVF Inc., and Mark Lampert (collectively the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a section 13G group that collectively owns more than 10% of the Issuer's oustanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
- Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
- Represents shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2.
- Represents shares of Common Stock owned directly by BVLLC. As the manager of BVLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC.
- Pursuant to the operating agreement of BVLLC, Partners is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVLLC, in the Common Stock and other securities of the Issuer and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
- Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request